SALT LAKE CITY — The first case of a rare blood-clotting condition thought to be linked to the Johnson & Johnson COVID-19 vaccine has been diagnosed in Utah.
A male patient was recently diagnosed with vaccine-induced Thrombotic Thrombocytopenia, also known as VITT, at the University of Utah Hospital, U. health officials said in a Wednesday news release.
The patient was treated and is now recovering at home, according to the release. Health officials didn’t provide any more detail about the case in the release. A news conference is scheduled for 2:30 p.m. Wednesday where doctors are expected to further discuss the case.
The blood clot condition led to a nationwide pause on administration of the Johnson & Johnson vaccine last month after six cases were reported among over 6 million people who received the vaccine. The pause was lifted on April 23 after federal regulators determined the vaccine’s continued use was safe.
This story will be updated.